WO2012027882A1 - Composition pharmaceutique pour traiter l'insomnie et procédé de préparation de celui-ci - Google Patents

Composition pharmaceutique pour traiter l'insomnie et procédé de préparation de celui-ci Download PDF

Info

Publication number
WO2012027882A1
WO2012027882A1 PCT/CN2010/076472 CN2010076472W WO2012027882A1 WO 2012027882 A1 WO2012027882 A1 WO 2012027882A1 CN 2010076472 W CN2010076472 W CN 2010076472W WO 2012027882 A1 WO2012027882 A1 WO 2012027882A1
Authority
WO
WIPO (PCT)
Prior art keywords
extract
pharmaceutical composition
lily
composition according
mulberry
Prior art date
Application number
PCT/CN2010/076472
Other languages
English (en)
Chinese (zh)
Inventor
吴以岭
Original Assignee
河北以岭医药研究院有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 河北以岭医药研究院有限公司 filed Critical 河北以岭医药研究院有限公司
Priority to SG2013013719A priority Critical patent/SG188283A1/en
Priority to RU2013112349/15A priority patent/RU2548756C2/ru
Priority to PCT/CN2010/076472 priority patent/WO2012027882A1/fr
Priority to MYPI2013000612A priority patent/MY170194A/en
Priority to KR1020137007571A priority patent/KR101457315B1/ko
Publication of WO2012027882A1 publication Critical patent/WO2012027882A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/06—Fungi, e.g. yeasts
    • A61K36/07—Basidiomycota, e.g. Cryptococcus
    • A61K36/074—Ganoderma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/06—Fungi, e.g. yeasts
    • A61K36/07—Basidiomycota, e.g. Cryptococcus
    • A61K36/076—Poria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/60—Moraceae (Mulberry family), e.g. breadfruit or fig
    • A61K36/605—Morus (mulberry)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/70—Polygonaceae (Buckwheat family), e.g. spineflower or dock
    • A61K36/704—Polygonum, e.g. knotweed
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/72—Rhamnaceae (Buckthorn family), e.g. buckthorn, chewstick or umbrella-tree
    • A61K36/725—Ziziphus, e.g. jujube
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
    • A61K36/8964—Anemarrhena
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Definitions

  • the invention belongs to the field of Chinese herbal medicine, and relates to a pharmaceutical composition and a preparation method thereof, wherein the pharmaceutical composition comprises Polygonum multiflorum and/or an extract thereof, Suanzaoren and/or an extract thereof, mulberry and/or an extract thereof, which can be used for Treat insomnia.
  • Insomnia is an unsatisfactory condition for the quality and quantity of sleep that lasts for a long time. Insomnia is a common clinical disease and frequently-occurring disease. Clinical symptoms can be manifested as: difficulty falling asleep, sleeping and waking up, not sleeping after waking up, waking up early in the morning, waking up when sleeping, not falling asleep all night, not sleeping deeply or sleeping Loss of feeling can be accompanied by multiple dreams. In addition, it can cause discomfort, fatigue, decreased mental activity, or impede social function. According to some data, about 20% of people have sleep disorders at the age of 20; they increase to 50% by the age of 55; they rise to 90% at the age of 80.
  • insomnia is as high as 10%-20%.
  • the Sanofi Sleep Survey of the Chinese Medical Association's Psychiatric Branch showed that 25.9% of people thought they had sleep disorders and started 2 years ago (median).
  • the athene scale 45.4% of people have unsatisfactory sleep quality, of which 28% are insomnia, 17.4% are suspicious insomnia (Zhang Xiaohong, China Medical Tribune, October 10, 2002, issue 831) .
  • Chinese medicine has a long history of treating non-caries.
  • Chinese medicine treatment of insomnia starts from the overall concept, syndrome differentiation and treatment, the curative effect is long-lasting, and the safety is good, and the patient's medication compliance is high. Therefore, people are seeking to prevent insomnia under the guidance of traditional Chinese medicine theory, and the need to use drugs prepared from natural Chinese herbal medicines to treat insomnia is also more intense.
  • the present invention provides a pharmaceutical composition
  • a pharmaceutical composition comprising Polygonum and/or its extract, Suanzaoren and/or an extract thereof, mulberry and/or an extract thereof.
  • the pharmaceutical composition according to the present invention further comprises Ganoderma lucidum and/or an extract thereof, lily and/or an extract thereof, an imaginary mother and/or an extract thereof, salvia miltiorrhiza and/or an extract thereof , chrysanthemum and / or its extract, sputum and / or its extract.
  • the pharmaceutical composition according to the present invention further comprises acacia and/or an extract thereof.
  • the extracts are each independently a solvent extract.
  • the solvent may be any suitable solvent such as water, ethanol, aqueous ethanol, supercritical carbon dioxide or any mixture thereof.
  • the pharmaceutical composition is prepared from the following bulk parts by weight: Polygonum multiflorum 150-270, Suanzaoren 145-275, Mulberry 160-255.
  • the pharmaceutical composition is prepared from the following bulk parts by weight: Polygonum multiflorum 150-270, Suanzaoren 145-275, Mulberry 160-255, Ganoderma lucidum 80-135, Lily 75-160, Known Mother 50-110, Salvia 120-200, Chrysanthemum 45-120, ⁇ 75-145.
  • the pharmaceutical composition is prepared from the following bulk parts by weight: Polygonum multiflorum 150-270, Suanzaoren 145-275, Mulberry 160-255, Ganoderma lucidum 80-135, Lily 75-160, Known Mother 50-110, Salvia 120-200, Chrysanthemum 45-120, ⁇ 75-145, Albizia 165-288.
  • the weight ratio of the drug substance is: Polygonum multiflorum 158, Suanzaoren 270, Mulberry 165, Ganoderma lucidum 135, Lily 80, Zhimu 110, Salvia miltiorrhiza 125, Chrysanthemum 118, ⁇ 80, Albizia 280.
  • the weight ratio of the drug substance is: Polygonum multiflorum 265, Suanzaoren 147, Mulberry 250, Ganoderma lucidum 81, Lily 158, Zhimu 55, Salvia miltiorrhiza 188, Chrysanthemum 50, ⁇ 145, Albizia 170.
  • the weight ratio of the drug substance is: Polygonum multiflorum 225, Suanzaoren 163, Mulberry 220, Ganoderma lucidum 83, Lily 113, Zhimu 50, Salvia miltiorrhiza 190, Chrysanthemum 45, ⁇ 113, Albizia 178.
  • the weight ratio of the drug substance is: Polygonum multiflorum 165, Suanzaoren 228, Mulberry 173, Ganoderma lucidum 110, Lily 75, Zhimu 75, Salvia miltiorrhiza 150, Chrysanthemum 78, ⁇ 78, Albizia 218.
  • the weight ratio of the drug substance is: Polygonum multiflorum 200, Suanzaoren 200, Mulberry 200, Ganoderma lucidum 100, Lily 100, Zhimu 66.7, Danshen 166.7, Chrysanthemum 66.7, ⁇ 100, Albizia 200.
  • the pharmaceutical composition contains not less than 0.5 mg, preferably not less than 1.0 mg, more preferably not less than 1.5 mg, of 2,3 per gram of the dry weight of the pharmaceutical composition.
  • 5,4,-Tetrahydroxystilbene-2-0- ⁇ -D-glucoside (mainly from Polygonum multiflorum or its extract).
  • the pharmaceutical composition is in the form of a capsule, a tablet, a powder, an oral solution, a soft capsule, a pill, an elixir, a syrup, a suppository, a gel, a spray. Or an injection.
  • the preparation of the pharmaceutical composition comprises making one or more of the drug substances separately or together into an extract.
  • the preparation of the pharmaceutical composition comprises: weighing the drug substance in the proportion by weight, soaking in water for 20-40 minutes, boiling and boiling for 30-40 minutes, filtering, adding water and boiling, frying Boil for 25-30 minutes, filter, and combine the two filtrates.
  • the preparation of the pharmaceutical composition comprises the steps of: a) preparing an extract of Polygonum multiflorum, Anemarrhena asphodelus and Suanzaoren;
  • step d) using the alcohol extract extract of step a), the water extract extract of step b) and the lily powder of step c) as the active ingredient of the pharmaceutical composition.
  • the preparation of the pharmaceutical composition comprises the following steps: a) weighing the Polygonum multiflorum, the mother and the jujube kernel according to the weight ratio, adding 6-12 times the amount of 30%-70% ethanol, heating and refluxing Extracting 1-3 times, each time 1-3 hours, the extract is filtered, combined, and the ethanol is recovered under reduced pressure, and concentrated to 60X: the relative density is determined to be 1.10-1.15, and the alcohol extract extract is obtained;
  • step d) using the alcohol extract extract of step a), the water extract extract of step b) and the lily powder of step c) as the active ingredient of the pharmaceutical composition.
  • the active ingredient can be formulated with the optional pharmaceutical excipients in the desired dosage form.
  • the dosage form of the pharmaceutical composition of the present invention may be any suitable dosage form, such as a capsule, Tablets, powders, oral liquids, soft gelatin pills, pills, tinctures, syrups, suppositories, gels, sprays or injections.
  • pharmaceutically acceptable excipients such as fillers, disintegrants, lubricants, suspending agents, binders, sweeteners, flavoring agents, preservatives and the like may be added in the preparation of these dosage forms.
  • Fillers include: starch, pregelatinized starch, lactose, mannitol, quercetin, microcrystalline cellulose, sucrose, and the like.
  • the disintegrating agent includes: starch, pregelatinized starch, microcrystalline cellulose, sodium carboxymethyl starch, crosslinked polyvinylpyrrolidone, low-substituted hydroxypropylcellulose, croscarmellose sodium, and the like.
  • Lubricants include: magnesium stearate, sodium lauryl sulfate, talc, silica, and the like.
  • Suspending agents include: polyvinylpyrrolidone, microcrystalline cellulose, sucrose, agar, hydroxypropyl decyl cellulose, and the like. Binders include, starch syrup, polyvinylpyrrolidone, hydroxypropyl decyl cellulose, and the like.
  • Sweeteners include: sodium saccharin, aspartame, sucrose, cyclamate, glycyrrhetinic acid, and the like.
  • Flavoring agents include: sweeteners and various flavors. Preservatives include: parabens, benzoic acid, sodium benzoate, sorbic acid and its salts, benzalkonium bromide, chlorhexidine acetate, eucalyptus oil, etc.
  • compositions of the invention can be prepared by a variety of methods. Such methods of preparation are well known to those of ordinary skill in the art and are taught in various technical documents, such as Remington's Pharmaceutical Handbook, and the like. These methods include conventional formulation preparation techniques such as mixing, dissolving, emulsification, suspending, and the like.
  • the method for preparing a tablet of the pharmaceutical composition of the present invention comprises the following steps:
  • step d) drying and granulating the alcohol extract extract obtained in the step a) and the water extract extract of the step b) and the lily powder obtained in the step c), after adding the appropriate excipients, mixing, tableting, coating, ie, Got it.
  • the method for preparing a tablet of the pharmaceutical composition of the present invention preferably comprises the following steps:
  • step d) adding the lily powder obtained in the step c) to the raw material container of the spray drying granulator, spraying the alcohol extract extract obtained in the step a) and the water extract extract of the step b), spraying and granulating, after the whole granule, adding 0.5% magnesium stearate, mixed, compressed, coated, that is.
  • the preparation method of the pharmaceutical composition decoction of the present invention comprises: weighing the Polygonum multiflorum, Suanzaoren, Mulberry, Ganoderma lucidum, Lily, Zhimu, Salvia, Chrysanthemum, Chinese wolfberry and Albizia, in a frying pan, adding water to the first time
  • the surface of the drug is 3-5cm, soak for 20-40 minutes, boil for 30-40 minutes, filter, add water to l-3cm beyond the surface of the drug, boil for 25-30 minutes, filter and combine the two filtrates. .
  • the preparation method of the pharmaceutical composition water pellet of the invention comprises:
  • Step a) The obtained alcohol extracting paste and the water extracting paste of the step b) and the obtained lily powder obtained in the step c) are collectively made into pills, that is, obtained.
  • the capsules, powders, oral liquids, soft capsules, pills, elixirs, syrups, suppositories, gels, sprays and injections of the pharmaceutical composition of the present invention may each be the drug substance of the pharmaceutical composition of the present invention or the drug of the present invention.
  • the active ingredient of the composition is prepared according to conventional pharmaceutical methods.
  • the pharmaceutical compositions of the invention can be administered to a variety of animals, including mammals, particularly humans.
  • the dosage can be determined by the medical practitioner based on the condition of the subject, including, for example, the severity of the disease, general health, weight, age, and the like of the patient.
  • the pharmaceutical compositions of this invention may be administered by a variety of suitable routes including, for example, oral, injection, transdermal, transdermal, and topical administration.
  • the frequency of administration of the pharmaceutical compositions of the present invention can also be determined by a variety of factors including, for example, the particular condition to be treated, the general health of the subject, and the like.
  • the pharmaceutical composition of the present invention is used in an amount of 14-20 g/day, based on the total weight of the raw material drug, and can be taken once a day or in 2-4 times, preferably 16.8 g/day. Take it 3 times.
  • Polygonum POLYGONI MULTIFLORI RADIX. This product is the dried root of Polygonum multiflorum Thunb. When the leaves are withered in the autumn and winter seasons, they are cut, the ends are cut, washed, and the big ones are cut into pieces and dried.
  • Suanzaoren ZIZIPHI SPINOSAE SEMEN. This product is a dry mature seed of the genus Rhamnaceae, Ziziphus jujuba Mill var. spinosa (Bunge) Hu ex H. F.Chou. Mature fruit is harvested at the end of autumn and winter, the flesh and core shell are removed, the seeds are collected and dried.
  • Stir-fried jujube kernel Take the sour jujube kernel, according to the method of clearing and frying (Chinese Pharmacopoeia 2010 Appendix II D) stir-fry until the bulge, the color becomes slightly deeper. Broken when used.
  • Mulberry MORIFRUCTUS. This product is the dried ear of the Moraceae fl. When the fruit turns red from April to June, it is harvested, dried, or slightly steamed and dried.
  • Ganoderma lucidum GANODERMA. This product is a dry fruiting body of the polyporaceae fungus Ganoderma lucidum (Leyss. ex Fr.) Karst. or Ganoderma sinense Zhao , Xu et Zhang. Harvested throughout the year, remove impurities, cut off the lower end of the stipe with deadwood, silt or culture substrate, dry or dry at 40 ⁇ 50X: dry.
  • Zhimu ANEMARRHENAE RHIZOMA. This product is the lily of the lily family Anemarrhena asphodeloides Bge. thousand, ⁇ . Excavation in the spring and autumn seasons, removing the roots and sediment, drying, known as "Mao Zhimu"; or removing the skin and drying.
  • Salvia SALVIAE MILTIORRHIZAE RADIX ET RHIZOMA. Ben Salvia miltiorrhiza Dry roots and rhizomes of e ⁇ . Excavate in the spring and autumn, remove the sediment and dry.
  • Chrysanthemum CHRYSANTHEMI FLOS. This product is a dried flower head of Chrysanthemum morifolium flwifl. When the flowers are in full bloom from September to November, they are harvested in batches, dried or toasted, or smoked, steamed and dried. According to the origin and processing methods, the medicinal materials are divided into “Jiju”, “Jiju”, “Gongju” and "Hangju”.
  • Albizia ALBIZIAE FWS. This product is a dry inflorescence of the legume Acacia Albizia ji ibrissin Duraz. When the summer flowers are open, choose sunny harvest and dry in time.
  • the traditional Chinese medicines of the present invention can be replaced by traditional Chinese medicines having the same or similar effects, and these medicines can be processed according to the "National Chinese Medicine Processing Regulations" or "Chinese Medicine Dictionary”.
  • Polygonum multiflorum can be replaced by Polygonum multiflorum
  • sour jujube kernel can be replaced by fried jujube kernel.
  • the effect of replacement can be better than that of using original drug, but it belongs to the present invention.
  • the invention also provides the use of the pharmaceutical composition for the treatment of symptoms such as insomnia, forgetfulness, head pull, distress and/or weakness of the waist and knees.
  • the invention also provides the use of the pharmaceutical composition for sedation, hypnosis, promoting memory, anti-fatigue and/or analgesia.
  • the invention provides a method of treating insomnia comprising administering the pharmaceutical composition to a patient suffering from insomnia.
  • the functional ingredients of the pharmaceutical composition of the present invention are: Yishen Jiannao, Yangxinshen, for insomnia, syndromes of heart and kidney deficiency, symptoms of sleep disorders, such as difficulty falling asleep, not sleeping deeply, Easy to wake up, wake up early, dream more, etc., with forgetfulness, head-holding, palpitations, distress, weak waist and knees.
  • Example 1 Preparation of the pharmaceutical composition tablet of the present invention (also referred to as: Jiannao Anshen Tablet)
  • Raw material medicine Polygonum multiflorum 200 g; Suanzaoren 200 g; Mulberry 200 g; Ganoderma lucidum 100 g; Lily 100 g; Zhimu 66.7 Gram; Danshen 166.7 g; Chrysanthemum 66.7 g; ⁇ 100 g; Albizia 200 g.
  • Raw material medicine Polygonum multiflorum 158g; Suanzaoren 270g; Mulberry 165g; Ganoderma lucidum 135g; Lily 80g; Zhimu 110g; Salvia: 125g; Chrysanthemum 118g; ⁇ 80g; Albizia 280g.
  • the alcohol extract extract obtained in the step a) and the water extract extract of the step b) and the fine powder obtained in the step c) are dried and granulated, and after the whole granule, the appropriate excipients are added, the hook is mixed, and the plastic mash is filled.
  • Raw material medicine Polygonum multiflorum 265 g; Suanzaoren 147 g; Mulberry 250 g; Ganoderma lucidum 81 g; Lily 158 g; Zhimu 55 g; Salvia miltiorrhiza 188 g; Chrysanthemum 50 g; ⁇ 145 g; Acacia flower 170 g.
  • Raw material medicine Polygonum multiflorum 225g; Suanzaoren 163g; Mulberry 220g; Ganoderma lucidum 83g; Lily 113g; Zhimu 50g; Salvia miltiorrhiza 190g; Chrysanthemum 45g; ⁇ 113g; Albizia 178g.
  • Raw material medicine 225 grams of Polygonum multiflorum; 163 grams of Suanzaoren; 220 grams of mulberry; Ganoderma lucidum 83 ⁇ ; lily 113 grams; 50 grams of Zhimu; 190 grams of Salvia; 45 grams of chrysanthemum; ⁇ 113 grams; 178 grams of Acacia.
  • Raw material medicine Polygonum multiflorum 165g; Suanzaoren 228g; Mulberry 173g; Ganoderma lucidum 110g; Lily 75g; Zhimu 75g; Salvia 150g; Chrysanthemum 78g; ⁇ 78g; Albizia 218g.
  • Example 7 Preparation of the pharmaceutical composition tincture of the present invention
  • Raw material medicine Polygonum multiflorum 158g; Suanzaoren 270g; Mulberry 165g; Ganoderma lucidum 135g; Lily 80g; Zhimu 110g; Salvia: 125g; Chrysanthemum 118g; ⁇ 80g; Albizia 280g.
  • Raw material medicine Polygonum multiflorum 265 g; Suanzaoren 147 g; Mulberry 250 g; Ganoderma lucidum 81 g; Lily 158 g; Zhimu 55 g; Salvia miltiorrhiza 188 g; Chrysanthemum 50 g; ⁇ 145 g; Acacia flower 170 g.
  • Preparation method According to the conventional method (Cao Chunlin, Traditional Chinese Medicine Pharmacy, Shanghai Science and Technology Press, November 1986, 1st edition, October 1993, 8th printing: 166-170, preparation method of syrup) 10000ml, divided into 10ml / support.
  • Example 9 Preparation of a suppository of the pharmaceutical composition of the present invention
  • Raw material medicine Polygonum multiflorum 158g; Suanzaoren 270g; Mulberry 165g; Ganoderma lucidum 135g; Lily 80g; Zhimu 110g; Salvia: 125g; Chrysanthemum 118g; ⁇ 80g; Albizia 280g.
  • Preparation method According to the conventional method (Cao Chunlin, Traditional Chinese Medicine Pharmacy, Shanghai Science and Technology Press, November 1986, 1st edition, October 1993, 8th printing: preparation method of suppository in 352-361), suppository 500 is prepared. Granules, 0.5 g / granules.
  • Raw material medicine Polygonum multiflorum 225g; Suanzaoren 163g; Mulberry 220g; Ganoderma lucidum 83g; Lily 113g; Zhimu 50g; Salvia miltiorrhiza 190g; Chrysanthemum 45g; ⁇ 113g; Albizia 178g.
  • Preparation method According to the conventional method (Cao Chunlin, Traditional Chinese Medicine Pharmacy, Shanghai Science and Technology Press, November 1986, 1st edition, October 1993, 8th printing: 349-350, preparation method of gelling agent)
  • the gelling agent is 3000 g and is packed into 10 g / stick.
  • Example 11 Preparation of a pharmaceutical composition spray of the present invention
  • Raw material medicine 225 grams of Polygonum multiflorum; 163 grams of Suanzaoren; 220 grams of mulberry; 83 grams of Ganoderma lucidum; 113 grams of lily; 50 grams of Zhimu; 190 grams of Salvia; 45 grams of chrysanthemum; 113 grams of eucalyptus; Preparation method: According to the conventional method (Cao Chunlin, Traditional Chinese Medicine Pharmacy, Shanghai Science and Technology Press, November 1986, 1st edition, October 1993, 8th printing: 454-466, preparation method of spray) 10000ml, divided into 100ml / support.
  • Raw material medicine Polygonum multiflorum 165g; Suanzaoren 228g; Mulberry 173g; Ganoderma lucidum 110g; Lily 75g; Zhimu 75g; Salvia 150g; Chrysanthemum 78g; ⁇ 78g; Albizia 218g.
  • Preparation method According to the conventional method (Cao Chunlin, Chinese Medicine Pharmacy, Shanghai Science and Technology Press, November 1986, 1st edition, October 1993, 8th printing: 364-4193, preparation method of injection), injection 1000 Branch, 5ml / branch.
  • Example 14 Preparation of the pharmaceutical composition water pellet of the present invention
  • the following pharmacological test was carried out using the tablet prepared by the method of Example 1 (hereinafter referred to as the drug of the present invention).
  • mice Healthy Kunming mice, clean grade, male, 90, weight 18 ⁇ 22g, purchased from Hebei Experimental Animal Center, license number: SCXK ( ⁇ ) 2003 - 1 - 003, certificate number: DK0409-0040, kept in The pharmacology room of the Lingling Institute, light 12 hours / day, temperature 20 ⁇ 23:, relative humidity 40 ⁇ 60%.
  • the mice were caged, 6 per cage.
  • the mouse feed is a full-price pellet feed provided by the Experimental Animal Center of Hebei province to maintain adequate drinking water. Adaptive feeding for three days.
  • the medicament of the present invention corresponds to 3.47 g of crude drug/g, and the amount of human is 17.0 g of crude drug/day, i.e., 0.28 g of crude drug/kg of body weight (standard body weight of 60 kg).
  • a suspension was prepared with 0.5% CMC-Na, 4: stored.
  • the term "raw drug” means the aforementioned "raw drug”
  • the amount of "raw drug” means the amount of "raw drug” converted.
  • Anshen Bunao Liquid made from antler, Shouwu, Epimedium, dried ginger, jujube, vitamin B1, Indications: Brain and soothe the nerves, replenishing the marrow, replenishing qi and nourishing, often used for nerve fading, insomnia , forgetfulness, head-holding, fatigue, produced by Jilin Jidong Yanbian Pharmaceutical Co., Ltd. National medicine standard word: Z22022453, adult clinical dosage: 20ml/d, batch number: 040269. Estrozolam tablets, which are benzodiazepine anxiolytics, can cause inhibition of different parts of the central nervous system. With the increase of drug dosage, clinical manifestations can range from mild sedation to hypnosis and even coma.
  • the AB204-N electronic analytical balance was purchased from METTLER TOLEDO Instruments (Shanghai) Co., Ltd.
  • the drug of the present invention was set to 5.6 g of crude drug/kg, 2.8 g of crude drug/kg and 1.4 g of crude drug/kg, which were respectively equivalent to 20, 10, and 5 times of the clinical human dose (0.28 g of crude drug/kg).
  • the Anshen Bunao Solution 13ml/kg group and the estazolam 2.67mg/kg group were set.
  • mice were divided into 6 groups, as shown in Table 1.
  • Table 1 Effect of the drug of the present invention on spontaneous activity of mice Group dose Animals (only) equivalent to clinical multiple relationship Blank control group - 12 - Anshen Bunao Liquid Group 13ml/kg 12 39
  • the medicine of the invention 8. 8g crude medicine /kg 12 10
  • the concentration of each group of the drug of the present invention was 0.08 g dry powder/ml, 0.04 g dry powder/ml, 0.02 g dry powder/ml, and the concentration of the Anshen Bunao solution group was 0.65 ml liquid/ml, estazolam.
  • the concentration of the group administered was 0.13 mg/ml. Oral administration of 0.2 ml/10 g per day was consistent with the recommended oral route for clinical use. For 7 consecutive days, the estazolam group was administered only once on the 7th day.
  • mice were trained once a day in the morning, afternoon and evening, and each time they were adapted for 5 minutes, the number of spontaneous activities in lOmin was recorded, and 72 mice with an average of 150-250 times/lOmin were enrolled in the experiment. After the last administration, the number of autonomous activities was measured after lh, and the number of spontaneous activities of the mice within 10 minutes was recorded.
  • the medicament of the present invention can reduce the number of spontaneous activities of mice, and confirms that the medicament of the present invention has a sedative effect.
  • mice Healthy Kunming mice, clean grade, male, 72, weighing 18 ⁇ 22g, purchased from Hebei Experimental Animal Center, license number: SCXK ( ⁇ ) 2003 - 1 - 003, certificate number: DK0409-0016. It is kept in the pharmacology room of Yiling Research Institute, with illumination for 12 hours/day, temperature of 20 ⁇ 23:, relative humidity of 40 ⁇ 60%. The mice were caged, 6 per cage. The mouse feed is a full-price pellet feed provided by the Experimental Animal Center of Hebei province to maintain adequate drinking water. Adaptive feeding for three days.
  • the medicament of the present invention is equivalent to 3.47 g of crude drug/g dry powder, and the amount of human is 17.0 g of crude drug/day, that is, 0.28 g of crude drug/kg body weight (standard body weight of 60 kg).
  • the suspension was made up with 0.5% CMC-Na, 4 X: stored.
  • Anshen Bunao Liquid consisting of antler, shouwu, epimedium, dried ginger, jujube, vitamin B1, indications: Jiannao Shenshen, spermatozoa, qi and nourishing, often used for nerve fading, insomnia, Forgetfulness, head-to-head, fatigue, produced by Jilin Jidong Yanbian Pharmaceutical Co., Ltd., Chinese medicine standard: Z22022453, adult clinical dosage: 20ml/d, batch number: 040269.
  • Estrozolam tablets which are benzodiazepine anxiolytics, can cause inhibition of different parts of the central nervous system. With the increase of drug dosage, clinical manifestations can range from mild sedation to hypnosis and even coma.
  • the drug of the present invention was set to 5.6 g of crude drug/kg, 2.8 g of crude drug/kg and 1.4 g of crude drug/kg, which were respectively equivalent to 20, 10, and 5 times of the clinical human dose (0.28 g of crude drug/kg).
  • the Anshen Bunao Solution 13ml/kg group and the estazolam 2.67mg/kg group were set.
  • the mice were divided into 6 groups, as shown in Table 3.
  • Table 3 Effect of the drug of the present invention on sleep time of mice in pentobarbital sodium Groups Dose Animals (only) Equivalent to clinical multiple relationship Model control group - 12 - Anshen Bunao Liquid Group 13 ml/kg 12 39
  • the drug group of the invention 8. 8g crude drug /kg 12 10
  • the concentration of each group of the drug of the present invention was 0.08 g dry powder/ml, 0.04 g dry powder/ml, 0.02 g dry powder/ml, and the concentration of the Anshen Bunao solution group was 0.65 ml liquid/ml, estazolam.
  • the concentration of the group administered was 0.13 mg/ml. Oral administration of 0.2 ml/10 g per day was consistent with the recommended oral route for clinical use. For 7 consecutive days, the estazolam group was administered only once on the 7th day.
  • mice 45mg/kg.
  • pentobarbital sodium was intraperitoneally injected, and the sleep time of the mice was recorded (the time when the righting reflex disappeared until the righting reflex was restored).
  • the drug group of the invention 8. 8g crude drug / kg 57. 90 ⁇ 17 ⁇ 04**
  • the medicament of the present invention has the effect of prolonging the sleep time of mice induced by sodium pentobarbital.
  • the drug of the invention promotes memory
  • mice Healthy Kunming mice, clean grade, male, 72, weighing 18 ⁇ 22g, purchased from Hebei Experimental Animal Center, license number: SCXK ( ⁇ ) 2003 - 1 - 003, No.: DK0504-0019. Raised in the cold research laboratory, light 12 hours / day, temperature 20 ⁇ 23 : , relative humidity 40 ⁇ 60%. The mice were housed in cages, 6 per cage. The mouse feed is a full-price pellet feed provided by the Experimental Animal Center of Hebei province to maintain adequate drinking water. Adaptive feeding for three days.
  • the medicine of the invention is provided by Shijiazhuang Yiling Pharmaceutical Co., Ltd., batch number:
  • Huperzine is a reversible, highly selective acetylcholinesterase inhibitor.
  • Henan Zhulin Zhongsheng Pharmaceutical Co., Ltd. produces, Chinese medicine quasi-word H10940156, specifications: 0.05mg / piece, batch number: 050201.
  • the drug of the present invention was set to 5.6 g of crude drug/kg, 2.8 g of crude drug/kg and 1.4 g of crude drug/kg, which were respectively equivalent to 20, 10, and 5 times of the clinical human dose (0.28 g of crude drug/kg).
  • the mice were divided into 6 groups, as shown in Table 5.
  • the drug group of the invention 8. 8g crude drug /kg 12 10
  • the administration concentrations of the respective groups of the present invention were 0.08 g of dry powder/ml, 0.04 g of dry powder/ml, and 0.02 g of dry powder/ml, respectively, and the concentration of the huperzine group was 0.02 mg/ml.
  • Oral administration of 0.2 ml/10 g per day was consistent with the clinically recommended oral route for 14 consecutive days.
  • mice On the 14th day, 30 minutes after the administration, the mice were intraperitoneally injected with 2 mg/kg of scopolamine hydrobromide to prepare a memory reproduction disorder model.
  • mice water temperature 24 ⁇ 26X:, water depth 10cm
  • the whole training is divided into 5 days, the 9th day A point, the 10th day B point, the 11th day B point, the 12th day S point, the 13th day S point, the training once a day, each time limit 2 minutes, timeout
  • the glass rod guides the animal to the steps.
  • the head of the mouse is facing the wall of the starting point when swimming begins. After performing S-point training, the mice were required to swim to the steps within 2 minutes or to eliminate them.
  • mice On the 14th day, 30 min after the administration, the mice were intraperitoneally injected with 2 m g /k g of scopolamine hydrobromide to prepare a memory reproduction disorder model. The test was carried out 30 minutes after modeling, and the mice started swimming from the S point, and the number of errors (the number of times entering the blind end) and the incubation period (the time from the S point to the step) were recorded.
  • the drug of the present invention has an effect of improving the memory disorder of mice caused by scopolamine.
  • the swimming latency of the 5.6 g crude drug/kg group of the present invention was shortened.
  • the swimming latency of the 5.6 g crude drug/kg group and the 2.8 g crude drug/kg group of the present invention was shortened. It is indicated that the medicament of the present invention has an effect of improving memory.
  • the swimming time of the 5.6 g crude drug/kg group of the drug of the present invention was prolonged, and the 2.8 g crude drug/kg and 1.4 g crude drug/kg group of the present invention had a tendency to prolong swimming time, respectively, 25.5% and 11.3%.
  • the 5.6, 2.8, and 1.4 g crude drug/kg groups of the present invention had a tendency to prolong the swing time, which were 93.6%, 55.9%, and 3.0%, respectively. It is indicated that the medicament of the invention has certain anti-fatigue effects.
  • the writhing latency of the 5.6 g crude drug/kg group of the present invention was prolonged, the number of writhing was decreased, and the writhing latency of the 2.8 g crude drug/kg group was prolonged, and the number of writhing was decreased.
  • the pain threshold of the 2.8 g crude drug/kg group of the drug of the present invention was prolonged. It is indicated that the medicament of the present invention has an analgesic effect.
  • the medicament of the present invention has sedative, hypnotic, memory-promoting, anti-fatigue and analgesic effects. use.
  • the recommended clinical dose of the pharmaceutical composition of the present invention is 17.0 g crude drug/day (standard weight 60 kg), and the toxicological test of the pharmaceutical composition of the present invention confirms that the maximum dose is 166.80 g crude drug/kg, and no acute toxicity is observed in the mouse. Reaction; 5.6, 11.2, 22.4g crude drug / kg continuous gavage for 3 months, no obvious toxicity in rats, can be recommended for clinical use.

Landscapes

  • Health & Medical Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Mycology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Medical Informatics (AREA)
  • Botany (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Anesthesiology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

La présente invention concerne une composition pharmaceutique pour traiter l'insomnie et un procédé de préparation de celui-ci, ladite composition pharmaceutique comprenant Radix Polygoni Multiflori et/ou des extraits de celui-ci, Semen Ziziphi Spinosae et/ou des extraits de celui-ci, Fructus Mori et/ou des extraits de celui-ci, Ganoderma et/ou des extraits de celui-ci, Bulbus Lilii et/ou des extraits de celui-ci, Rhizoma Anemarrhenae et/ou des extraits de celui-ci, Radix Salviae Miltiorrhizae et/ou des extraits de celui-ci, Flos Chrysanthemi et/ou des extraits de celui-ci, Poria et/ou des extraits de celui-ci, et Flos Albiziae et/ou des extraits de celui-ci. La composition pharmaceutique est utilisée pour traiter l'insomnie et les symptômes d'amnésie, vertige, lassitude, et douleur et faiblesse au niveau de la taille et des genoux, etc.
PCT/CN2010/076472 2010-08-30 2010-08-30 Composition pharmaceutique pour traiter l'insomnie et procédé de préparation de celui-ci WO2012027882A1 (fr)

Priority Applications (5)

Application Number Priority Date Filing Date Title
SG2013013719A SG188283A1 (en) 2010-08-30 2010-08-30 Pharmaceutical composition for treating insomnia and preparation method thereof
RU2013112349/15A RU2548756C2 (ru) 2010-08-30 2010-08-30 Фармацевтическая композиция для лечения бессоницы и способ получения
PCT/CN2010/076472 WO2012027882A1 (fr) 2010-08-30 2010-08-30 Composition pharmaceutique pour traiter l'insomnie et procédé de préparation de celui-ci
MYPI2013000612A MY170194A (en) 2010-08-30 2010-08-30 Pharmaceutical composition for treating insomnia and preparation method thereof
KR1020137007571A KR101457315B1 (ko) 2010-08-30 2010-08-30 불면증 치료용 약학적 조성물 및 그 제조 방법

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/CN2010/076472 WO2012027882A1 (fr) 2010-08-30 2010-08-30 Composition pharmaceutique pour traiter l'insomnie et procédé de préparation de celui-ci

Publications (1)

Publication Number Publication Date
WO2012027882A1 true WO2012027882A1 (fr) 2012-03-08

Family

ID=45772071

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2010/076472 WO2012027882A1 (fr) 2010-08-30 2010-08-30 Composition pharmaceutique pour traiter l'insomnie et procédé de préparation de celui-ci

Country Status (5)

Country Link
KR (1) KR101457315B1 (fr)
MY (1) MY170194A (fr)
RU (1) RU2548756C2 (fr)
SG (1) SG188283A1 (fr)
WO (1) WO2012027882A1 (fr)

Cited By (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102895345A (zh) * 2012-10-22 2013-01-30 重庆希尔安药业有限公司 治疗失眠的药物组合物
CN103127297A (zh) * 2013-03-23 2013-06-05 李艳 一种治疗恐惧性神经症的中药组合物及其制备方法
CN103169787A (zh) * 2012-11-30 2013-06-26 云南白药天颐茶品有限公司 一种具有提高睡眠质量延长深度睡眠时间的组合物及其应用
CN103599209A (zh) * 2013-11-28 2014-02-26 佘坤 一种治疗神经衰弱的中药
CN104056230A (zh) * 2014-06-26 2014-09-24 余明 一种治疗心脾两虚型失眠的中药组合物
KR20150004158A (ko) 2013-07-02 2015-01-12 경희대학교 산학협력단 고본 추출물을 유효성분으로 포함하는 불면증의 예방 또는 치료용 약학적 조성물
CN105232670A (zh) * 2015-11-11 2016-01-13 王书汉 一种枣树叶有效成分的提取方法及所得产品
CN107095985A (zh) * 2017-06-13 2017-08-29 邵竹蕾 一种用于治疗产后失眠征的中药冲剂及制备方法
CN108310330A (zh) * 2018-05-03 2018-07-24 郭亚方 一种治疗失眠的内服中药组合物
CN112568293A (zh) * 2020-12-23 2021-03-30 北京可利可徕科技有限公司 一种调节睡眠障碍的乳饮料及其制备方法
CN112807398A (zh) * 2021-01-21 2021-05-18 中国人民解放军军事科学院军事医学研究院 一种具有滋阴清热，养血安神功效的中药组合物
CN113509438A (zh) * 2021-04-28 2021-10-19 浙江工业大学 一种用于治疗失眠的西红花药物组合乳剂及其制备与应用
CN114081171A (zh) * 2020-08-09 2022-02-25 辽宁医学诊疗科技研发中心有限公司 一种具有辅助改善睡眠作用的功能性食品组合物

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104013694A (zh) * 2014-06-20 2014-09-03 苏州法莫生物技术有限公司 一种改善睡眠的中药组方
CN104013724A (zh) * 2014-06-20 2014-09-03 苏州法莫生物技术有限公司 一种改善睡眠的中药组合物
CN104013690A (zh) * 2014-06-20 2014-09-03 苏州法莫生物技术有限公司 改善睡眠的中药
CN104013691A (zh) * 2014-06-20 2014-09-03 苏州法莫生物技术有限公司 一种改善睡眠作用的颗粒剂
CN104873609A (zh) * 2015-04-30 2015-09-02 肖祥宇 一种治疗失眠的药物及其制备方法
KR101685631B1 (ko) * 2016-06-10 2016-12-13 순천대학교 산학협력단 숙면용 한방 방향제
KR20180098459A (ko) * 2017-02-24 2018-09-04 한국 한의학 연구원 백합 비늘줄기 추출물을 포함하는 인지장애의 예방 또는 치료용 약학 조성물
KR20200097460A (ko) 2019-02-08 2020-08-19 장영희 메타아르세나이트 염을 포함하는 불면증에 유용한 조성물
KR102590559B1 (ko) 2021-01-27 2023-10-18 에이치엠오건강드림영농조합법인 불면증 및 수면장애 질환의 예방, 개선 또는 치료용에 있어서 굼벵이 추출물을 유효성분으로 포함하는 조성물
WO2024122768A1 (fr) * 2022-12-09 2024-06-13 가톨릭관동대학교산학협력단 Composition pour prévenir ou améliorer l'insomnie, comprenant un extrait de poria cocos

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1857625A (zh) * 2006-03-24 2006-11-08 郭云华 一种强身益智保健品及其制备方法
CN101011549A (zh) * 2007-01-31 2007-08-08 张金桦 一种补益肝肾、健脑益智的药物及其制备方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3686063B2 (ja) * 2002-03-12 2005-08-24 末人 山上 睡眠障害の改善作用を有する健康補助食品
CN101301450A (zh) * 2008-06-25 2008-11-12 崔凤玉 一种治疗失眠症的药物
CN101524513B (zh) * 2009-04-07 2012-01-04 秭归县兴盛贸易有限责任公司 一种保健枕药芯
CN101543612B (zh) * 2009-05-12 2012-07-04 王秋贤 治疗恶性淋巴瘤的中药
CN101574499A (zh) * 2009-06-05 2009-11-11 李振爽 安神宁心胶囊

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1857625A (zh) * 2006-03-24 2006-11-08 郭云华 一种强身益智保健品及其制备方法
CN101011549A (zh) * 2007-01-31 2007-08-08 张金桦 一种补益肝肾、健脑益智的药物及其制备方法

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
LU JING ET AL.: "HPLC Determination of Stilbene Derivative in Radix Polygoni Multiflori", CHINESE JOURNAL OF PHARMACEUTICAL ANALYSIS, vol. 20, no. 2, 2000, pages 104 *

Cited By (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102895345A (zh) * 2012-10-22 2013-01-30 重庆希尔安药业有限公司 治疗失眠的药物组合物
CN103169787B (zh) * 2012-11-30 2014-11-26 云南白药天颐茶品有限公司 一种具有提高睡眠质量延长深度睡眠时间的组合物及其应用
CN103169787A (zh) * 2012-11-30 2013-06-26 云南白药天颐茶品有限公司 一种具有提高睡眠质量延长深度睡眠时间的组合物及其应用
CN103127297A (zh) * 2013-03-23 2013-06-05 李艳 一种治疗恐惧性神经症的中药组合物及其制备方法
KR20150004158A (ko) 2013-07-02 2015-01-12 경희대학교 산학협력단 고본 추출물을 유효성분으로 포함하는 불면증의 예방 또는 치료용 약학적 조성물
CN103599209A (zh) * 2013-11-28 2014-02-26 佘坤 一种治疗神经衰弱的中药
CN104056230A (zh) * 2014-06-26 2014-09-24 余明 一种治疗心脾两虚型失眠的中药组合物
CN104056230B (zh) * 2014-06-26 2017-06-23 余明 一种治疗心脾两虚型失眠的中药组合物
CN105232670A (zh) * 2015-11-11 2016-01-13 王书汉 一种枣树叶有效成分的提取方法及所得产品
CN107095985A (zh) * 2017-06-13 2017-08-29 邵竹蕾 一种用于治疗产后失眠征的中药冲剂及制备方法
CN108310330A (zh) * 2018-05-03 2018-07-24 郭亚方 一种治疗失眠的内服中药组合物
CN114081171A (zh) * 2020-08-09 2022-02-25 辽宁医学诊疗科技研发中心有限公司 一种具有辅助改善睡眠作用的功能性食品组合物
CN112568293A (zh) * 2020-12-23 2021-03-30 北京可利可徕科技有限公司 一种调节睡眠障碍的乳饮料及其制备方法
CN112807398A (zh) * 2021-01-21 2021-05-18 中国人民解放军军事科学院军事医学研究院 一种具有滋阴清热，养血安神功效的中药组合物
CN113509438A (zh) * 2021-04-28 2021-10-19 浙江工业大学 一种用于治疗失眠的西红花药物组合乳剂及其制备与应用

Also Published As

Publication number Publication date
MY170194A (en) 2019-07-09
KR101457315B1 (ko) 2014-11-20
KR20130062347A (ko) 2013-06-12
RU2013112349A (ru) 2014-10-10
RU2548756C2 (ru) 2015-04-20
SG188283A1 (en) 2013-04-30

Similar Documents

Publication Publication Date Title
WO2012027882A1 (fr) Composition pharmaceutique pour traiter l'insomnie et procédé de préparation de celui-ci
CN106806853B (zh) 一种缓解体力疲劳和/或提高缺氧耐受力的中药组合物、其制备方法和应用
WO2021208335A1 (fr) Composition de médecine traditionnelle chinoise capable d'éliminer les toxines, de supprimer la moiteur, et de décongestionner la gorge, et son application
CN112294924A (zh) 一种养心安神药物组合物及其制备方法和应用
CN102178721B (zh) 绞股蓝混悬液、提取物在制备治疗抗抑郁症药物中的应用
CN103223149B (zh) 一种治疗肺癌的中草药组合物
CN105456818A (zh) 一种含有艾叶的治疗失眠的中药组合物及其制备方法
CN105853766A (zh) 一种中药制剂在制备治疗原发性高血压药物中的用途
CN110742983B (zh) 一种用于治疗痛风急性发作的中药制剂及其制备方法
CN114470130B (zh) 一种治疗心脏神经官能症的中药组合物及其应用
CN107595870A (zh) 一种健脑安神的药物组合物、药物制剂及应用和制备方法
CN107753551B (zh) 一种具有降血压功能的组合物及其制备方法
CN113181205B (zh) 包括nmn的药物组合物及其应用
CN115252729B (zh) 一种治疗糖尿病的中药组合物及其应用
CN106177689A (zh) 一种具有清肺化痰止嗽作用的组合物及其制备方法
CN105288157A (zh) 一种具有宣肺平喘作用的中药组合物、制备方法及其应用
CN108175818B (zh) 一种治疗青光眼的中药组合物及其制备方法和用途
CN108606996A (zh) 一种具有改善免疫功能的药物组合物
CN102552399B (zh) 一种清热平肝的中药组合物及其制备方法
CN105250749A (zh) 一种治疗甲状腺腺瘤的中药及其制备方法
CN107714776A (zh) 一种止咳定喘制剂的制备方法
CN112402485A (zh) 植物提取物在抗产褥期精神综合症药物中的应用
CN104606510B (zh) 用于治疗肿瘤相关性睡眠障碍的铁皮石斛复方制剂
CN118286356A (en) Traditional Chinese medicine composition for treating headache and application thereof
CN102526192B (zh) 一种清热平肝的中药组合物及制备方法

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10856569

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 20137007571

Country of ref document: KR

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 2013112349

Country of ref document: RU

Kind code of ref document: A

122 Ep: pct application non-entry in european phase

Ref document number: 10856569

Country of ref document: EP

Kind code of ref document: A1